These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 33551306)

  • 41. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 42. Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options.
    Garg V; Oza AM
    Drugs; 2023 Oct; 83(15):1365-1385. PubMed ID: 37737434
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations.
    Vanacker H; Harter P; Labidi-Galy SI; Banerjee S; Oaknin A; Lorusso D; Ray-Coquard I
    Cancer Treat Rev; 2021 Sep; 99():102255. PubMed ID: 34332292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
    Luo L; Keyomarsi K
    Expert Opin Investig Drugs; 2022 Jun; 31(6):607-631. PubMed ID: 35435784
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
    Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
    Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
    [No Abstract]   [Full Text] [Related]  

  • 46. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
    Lightfoot M; Montemorano L; Bixel K
    Curr Oncol Rep; 2020 Feb; 22(3):29. PubMed ID: 32067102
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acquired
    Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
    Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
    PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
    Noordermeer SM; van Attikum H
    Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
    Vanacker H; Romeo C; Ray-Coquard I
    Curr Opin Oncol; 2019 Sep; 31(5):394-403. PubMed ID: 31335830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    Tan J; Zheng X; Li M; Ye F; Song C; Xu C; Zhang X; Li W; Wang Y; Zeng S; Li H; Chen G; Huang X; Ma D; Liu D; Gao Q
    Oncogene; 2021 Jun; 40(22):3845-3858. PubMed ID: 33966038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
    Serra V; Wang AT; Castroviejo-Bermejo M; Polanska UM; Palafox M; Herencia-Ropero A; Jones GN; Lai Z; Armenia J; Michopoulos F; Llop-Guevara A; Brough R; Gulati A; Pettitt SJ; Bulusu KC; Nikkilä J; Wilson Z; Hughes A; Wijnhoven PWG; Ahmed A; Bruna A; Gris-Oliver A; Guzman M; Rodríguez O; Grueso J; Arribas J; Cortés J; Saura C; Lau A; Critchlow S; Dougherty B; Caldas C; Mills GB; Barrett JC; Forment JV; Cadogan E; Lord CJ; Cruz C; Balmaña J; O'Connor MJ
    Clin Cancer Res; 2022 Oct; 28(20):4536-4550. PubMed ID: 35921524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    Chu YY; Yam C; Yamaguchi H; Hung MC
    J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
    Royfman R; Whiteley E; Noe O; Morand S; Creeden J; Stanbery L; Hamouda D; Nemunaitis J
    Future Oncol; 2021 Jul; 17(21):2817-2830. PubMed ID: 34058833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
    Perez JM; Twigg CAI; Guan W; Thomas SN
    J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
    Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
    Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
    Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
    Miller RE; El-Shakankery KH; Lee JY
    J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
    Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploration of poly (ADP-ribose) polymerase inhibitor resistance in the treatment of BRCA1/2-mutated cancer.
    Wu S; Yao X; Sun W; Jiang K; Hao J
    Genes Chromosomes Cancer; 2024 May; 63(5):e23243. PubMed ID: 38747337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.